AxoGen (AXGN)
(Delayed Data from NSDQ)
$13.16 USD
-0.08 (-0.60%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $13.13 -0.03 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.16 USD
-0.08 (-0.60%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $13.13 -0.03 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
Boston Scientific's ACURATE Prime Aortic Valve System Wins CE Mark
by Zacks Equity Research
BSX achieves CE Mark approval for the ACURATE Prime Aortic Valve System, its latest TAVR technology.
Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for AxoGen (AXGN) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 200% and 10.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVRx (CVRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of -27.45% and 0.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.
Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) second-quarter results are likely to reflect strong performance in the Diagnostics segment.
Lower Volume Likely to Hurt GE HealthCare's (GEHC) Q2 Earnings
by Zacks Equity Research
GE HealthCare's (GEHC) second-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line results may reflect better pricing.
Factors Setting the Tone for Ecolab's (ECL) Q2 Earnings
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.
CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2024 results are likely to reflect rising volumes across all channels.
Intuitive Surgical (ISRG) Hits All-Time High: Will It Go Higher?
by Zacks Equity Research
Intuitive Surgical (ISRG) reported robust quarterly performance last week, and its shares touched an all-time high. Will the company's fundamentals support further upside?
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AxoGen (AXGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
by Zacks Equity Research
AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.
Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
by Zacks Equity Research
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 40% and 1.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices (MASS) delivered earnings and revenue surprises of 10.81% and 6.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
by Zacks Equity Research
Protagonist Therapeutics, AxoGen, Western Digital and Phunware have been highlighted in this Screen of The Week article.
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -100% and 0.98%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
4 Must-Buy Stocks for Remarkable Earnings Acceleration
by Tirthankar Chakraborty
Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).
AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
AxoGen (AXGN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.